# q01 rev 0 - raw independent returns

tested_sha256: fbb841e51c467054da11e1f34541ebeada5fffc88b5df62b62403e261f51f3ff
Date: 2026-10-05. Runtime: Claude Code (VS Code), fresh Agent-tool subagents (Opus 5.5), each given
only the workspace root, its own packet path and the frozen question (closed-book: question only).
Returns below are the agents' final reports as delivered, unedited.

## Solver A (blind-solver, packet solver-1)

**answer:** −$0.15. The midpoint fell from $5.675 to $5.525.

**confidence:** high

**path:**
1. **Completion date (D08, D10).** D08 line 27: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 lines 49 and 593 repeat the date ("acquired on March 23, 2026").
2. **Range in force on March 23, 2026 (D07, January 22, 2026).** Line 31: "Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint." Line 283 in the guidance section says the same. Line 33 shows the deal had not yet closed: "Abbott continues to expect the transaction to close in the second quarter of 2026."
3. **The next update came after completion (D08, April 16, 2026).** Headline (line 15): "Updates Guidance to Reflect Acquisition of Exact Sciences". Line 203: "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences." This range was issued 24 days after the deal closed, so it was not in force at closing.
4. **July range (D10, July 16, 2026).** Line 29: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58." Line 289 gives the same figures.
5. **Calculation:**
   - At completion: (5.55 + 5.80) / 2 = 11.35 / 2 = $5.675
   - July: (5.45 + 5.60) / 2 = 11.05 / 2 = $5.525
   - Change: 5.525 − 5.675 = **−$0.150, so −$0.15**
   - Check: 5.675 / 5.15 (D07's 2025 adjusted EPS) = 1.102, which matches D07's "10 percent growth at the midpoint".
6. **No other 2026 guidance in the packet.**
   - D01–D04 contain only 2025 guidance.
   - D05 (deal announcement, November 20, 2025) has no EPS figures; the only "earnings" match is a contact name.
   - D06 is the by-laws and has no "2026", "guidance" or "EPS" matches.
   - D09 is a derivative-litigation settlement notice and D11 is a litigation settlement release; neither mentions guidance.

**minimal_documents:** D07, D08, D10.
- D07 gives the range in force at closing.
- D10 gives the July range and the closing date.
- D08 is needed to show that the intermediate $5.38–$5.58 range (cited in D10 only as the "previous range") was issued on April 16, after closing. D08 also gives the closing date.
- No other document in the packet can replace any of these three.

**readings:**
- **Main reading:** the range literally in force on March 23, 2026 was the January range, so the change is **−$0.15**.
- **Alternative reading:** take the "range in force when it completed" to mean the first range that reflected the acquisition, i.e. the April $5.38–$5.58 range, which D10 calls the "previous range". Its midpoint is $5.48, and 5.525 − 5.48 = +$0.045. That is +$0.05 with half-up rounding, or +$0.04 with half-even rounding. I consider this weaker, because that range did not exist on the completion date.

**gaps:**
- The packet has no Abbott document between January 22 and April 16, 2026. An unrecorded update between January 22 and March 23 (for example at an investor conference) can't be ruled out. Nothing in the packet suggests one, and D08's headline describes its update as reflecting the acquisition.
- D08 doesn't state its prior range explicitly (no "compared to previous range" wording), so the link back to D07 is by date order.
- Coverage:
  - Read in full: D08, D09, D11.
  - Read in part: D07 (lines 1–45 and 270–310), D10 (lines 1–60 and 280–309), D06 (first 40 lines).
  - Checked by keyword search only: D01–D06.
- docs/ holds only .txt sources, with no PDFs or layout files, so there were no original page images to check.

**contaminated:** no

## Solver B (blind-solver, packet solver-2)

answer: **−$0.15.** The midpoint fell from $5.675 to $5.525.

confidence: high

path:
1. **Closing date.** D08 (`text\D08.txt` line 27) says: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 line 183 says the same: "On March 23, 2026, Abbott completed the acquisition of Exact Sciences."
2. **Range in force on March 23, 2026.** It is D07, issued Jan. 22, 2026. Line 31 says: "Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint." Line 283 repeats the range. The deal had not closed yet. Line 33 says: "Abbott continues to expect the transaction to close in the second quarter of 2026."
3. **The next update came after closing.** D08, dated April 16, 2026, has the headline "Updates Guidance to Reflect Acquisition of Exact Sciences". Lines 31 and 203 give "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences." This range was issued on April 16, after the March 23 closing, so it was not in force when the deal closed.
4. **July 2026 range.** D10, dated July 16, 2026, line 29 says: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58." Line 289 restates it.
5. **Calculation.**
   - January midpoint: (5.55 + 5.80) / 2 = 5.675
   - July midpoint: (5.45 + 5.60) / 2 = 5.525
   - Change: 5.525 − 5.675 = −0.150, which is **−$0.15** to the nearest cent.
6. **Check against the source files.** The three ranges match the original source files exactly:
   - `D:\Dev\Docket\tasks\aq-00745\runs\q01-r0-v2-fbb841e51c467054da11e1f34541ebeada5fffc88b5df62b62403e261f51f3ff\solver-2\docs\abt_ex991_2026-01-22.txt`, lines 15, 29 and 281
   - `...\docs\abt_ex991_2026-04-16.txt`, lines 17, 29 and 201
   - `...\docs\abt_ex991_2026-07-16.txt`, lines 17, 27 and 287

minimal_documents: D07, D08, D10.
- D07 gives the January range.
- D10 gives the July range and the closing date.
- D08 is needed to date the $5.38–$5.58 range to April 16, after closing. D10 only calls it the "previous range" without a date.
- No other packet document can replace any of these:
  - D05 is the November 2025 deal announcement. Its only figures on financial impact are about revenue growth and gross margin, not EPS.
  - D06 is the company by-laws.
  - D09 is a notice of a shareholder derivative settlement.
  - D11 is the August 2026 settlement of the preterm infant formula lawsuits, with no guidance.
  - D01–D04 contain only 2025 EPS guidance.

readings:
- **Reading the April range as the one "in force at closing."** Someone might take this to mean the first range that reflected the completed acquisition: $5.38–$5.58, midpoint $5.48. The change would then be 5.525 − 5.48 = +$0.045. That is +$0.05 rounding half up, or +$0.04 rounding half to even. The dates don't support this reading, because April 16 is after March 23.
- **Adjusting for the $0.20 Exact Sciences dilution.** Comparing like for like this way isn't supported. D10 doesn't state the dilution included in the July range.

gaps:
- The packet has no Abbott guidance statement between Jan. 22 and April 16, 2026. D08 doesn't restate the earlier range. So "the January range was still in force on March 23" rests on two things: no packet document shows an update in between, and D08's headline says it "Updates Guidance".
- All documents were extracted as plain text, with no PDFs or layout files. Nothing was lost in extraction.
- Coverage: I read D07, D08 and D10 at the headline and guidance sections, and grepped them more broadly. For D05, D06, D09 and D11 I read the opening lines and grepped for EPS and guidance terms. I checked D01–D04 only by grep for EPS ranges.

contaminated: no

## Shortcut audit (shortcut-auditor, packet shortcut)

answer: **−$0.15.** The midpoint fell from $5.675 to $5.525.

verdict: clear

shortest_path:
1. **Closing date.** D08 (April 16, 2026), line 27: "On March 23, 2026, Abbott completed its acquisition of Exact Sciences". D10 says the same at lines 49, 183 and 593.
2. **Range in force on March 23.** D07 (January 22, 2026), lines 31 and 283: "Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80". Line 33 says Abbott "continues to expect the transaction to close in the second quarter of 2026." So the January range was still in force on March 23.
3. **The April range came after the close.** D08's headline is "Updates Guidance to Reflect Acquisition of Exact Sciences", and lines 19, 31 and 203 give "$5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences". It was issued April 16, 24 days after completion, so it was not in force on March 23.
4. **July range.** D10 (July 16, 2026), line 29: "Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58." Line 289 restates it.
5. **Calculation.** (5.55 + 5.80) / 2 = 5.675. (5.45 + 5.60) / 2 = 5.525. 5.525 − 5.675 = −0.150, so −$0.15. No rounding is needed.

sufficient_documents: D07 + D08 + D10, all three needed.
- D07 is the only document that states the January $5.55 to $5.80 range.
- D10 gives the July range.
- D08 dates the $5.38 to $5.58 range to April 16, after the close, and also gives the closing date. With only D07 and D10, you can't tell whether the "previous range" was issued before or after March 23; it could have come out at closing.
- No single document is enough. D10 alone gives the July range, the closing date and a "previous range", but those lead to the wrong answer.

searches:
- "Exact Sciences": found in D05, D07, D08 and D10.
- A guidance/projects/reaffirm/raises/narrows near EPS pattern across all 11 text files.
- "previous / prior / previously provided / compared to … range or guidance".
- 2026 EPS mentions in D01–D06: none.
- Literal values 5.55, 5.80, 5.675, 5.525, 5.48, 0.15, plus "midpoint", "initial guidance" and "January guidance" in D07–D11: the January range appears only in D07, and no later document gives a midpoint or change figure.
- D05 (deal announcement, November 20, 2025) searched for dilution, accretion, EPS and closing terms: closing expected in Q2 2026, no EPS guidance; line 133 is forward-looking boilerplate.
- Ruled out as non-guidance: D06 (bylaws), D09 (derivative-settlement notice, read in full), D11 (infant-formula litigation release).
- Read the headlines and guidance sections of D07, D08 and D10.
- I did not read question.txt or anything outside docs/ and text/. No contamination was encountered.

readings/gaps:
- **Trap reading.** Treating D10's "previous range" of $5.38 to $5.58 (midpoint $5.48) as the range in force at completion gives +$0.045. That is +$0.05 with half-up rounding or +$0.04 with half-even. I reject it because that range was issued April 16, after the March 23 close. Because D10 by itself looks complete, a single-document reader is likely to give this answer. That is a difficulty risk, not a shortcut.
- **Other reading.** If "in force when it completed" were taken to mean the first guidance that reflected the completion, you would get the same April range and the same +$0.045. The literal wording points to the date, so this reading is weaker.
- **Gap.** The packet has no document between January 22 and April 16, 2026, and D08 never names the range it replaced. The conclusion that the January range was still in force on March 23 rests on two things: no interim update appears in the packet, which looks like a complete run of Abbott's press-release exhibits (including bylaws and litigation notices), and D08's "Updates Guidance to Reflect Acquisition" headline. An unpublished interim update can't be ruled out, but nothing suggests one.
- **Difficulty risk.** The valid route is a simple date join across three documents plus easy midpoint arithmetic.

## Closed-book (closed-book-solver, question text only)

answer: −$0.20 (the midpoint was lowered). This is a best guess, not a recalled figure.
confidence: low
basis: I recall Abbott's January 2026 guidance for full-year 2026 adjusted diluted EPS as $5.55–$5.80, a midpoint of $5.675. That range left out the pending Exact Sciences deal. I'm assuming it was still the range in force when the deal closed. The July 2026 range is after my knowledge cutoff, so I don't know it. I estimated the change from deal dilution of roughly $0.20 in the first year, which is my own unverified figure. I also can't confirm the closing date, which decides whether the January or the April range was in force at completion.
contaminated: no. The only context present was generic session and environment details, nothing related to the question. No tools were called.
